
Beat and held: IOL's pivot from ibuprofen commodity to diversified API platform
non-ibu diversification · capacity utilization · EBITDA margin beat
BSE: 524164
P/L Snapshot
Q2 FY27 · standalone
Shareholding
Pattern breakdown
P/L Trends
(in crores)

non-ibu diversification · capacity utilization · EBITDA margin beat

non-ibu diversification · capacity utilization · EBITDA margin beat

pharma api · chemical segment · margin expansion
Corporate Events
Board Meeting
The meeting of the Board of Directors is scheduled to consid…
BSE Filing ↗Board Meeting
The 39th Annual General Meeting ("AGM") is scheduled to be h…
BSE Filing ↗Board Meeting
The Board of Directors meeting is scheduled to consider and …
BSE Filing ↗Board Meeting
consider and approve the Un-Audited Financial Results of the…
BSE Filing ↗Board Meeting
consider and approve the Audited Financial Results of the Co…
BSE Filing ↗Board Meeting
Consideration and approval of Audited Financial Results for …
BSE Filing ↗Board Meeting
Consider and approve Audited Financial Results for Quarter a…
BSE Filing ↗Board Meeting
Consider and approve Audited Financial Results for the quart…
BSE Filing ↗